Francesca Barone (@baroneexpmed) 's Twitter Profile
Francesca Barone

@baroneexpmed

Clinician scientist in love with experimental medicine.

ID: 966388043950194688

calendar_today21-02-2018 19:03:59

561 Tweet

371 Followers

325 Following

Candel Therapeutics (@candeltx) 's Twitter Profile Photo

President and CEO,Dr. Paul Peter Tak, MD, PhD, FMedSci, CSO Francesca Barone, MD, PhD, and VP of Finance & Corporate Controller, Charles Schoch are kicking off 2024 at the 42nd Annual J.P. Morgan Healthcare conference. Be sure to say hello! #JPMorgan2024 #JPM24

President and CEO,<a href="/paulpetertak/">Dr. Paul Peter Tak</a>, MD, PhD, FMedSci, CSO <a href="/baroneExpMed/">Francesca Barone</a>, MD, PhD, and VP of Finance &amp; Corporate Controller, Charles Schoch are kicking off 2024 at the 42nd Annual <a href="/JPMorgan/">J.P. Morgan</a> Healthcare conference. Be sure to say hello! 

#JPMorgan2024 #JPM24
Dr. Paul Peter Tak (@paulpetertak) 's Twitter Profile Photo

Posting comments about the interpretation of clinical trial data comes with a responsibility to get it absolutely right, especially as it relates to cancer patients who are urgently waiting for better treatments. Let's dissect why this post was misleading. A thread.

Francesca Barone (@baroneexpmed) 's Twitter Profile Photo

Late stage melanoma represents a life threatening unmet clinical need. Come and visit our poster during SITC to discuss our plans to leverage our first in class viral immunotherapy CAN-3110 to fight this terrible disease.

Dr. Paul Peter Tak (@paulpetertak) 's Twitter Profile Photo

We hope we will deliver the data and regulatory approvals in prostate cancer to enable a paradigm shift in how these patients will be treated in the future. #CandelTherapeutics #viral #immunotherapy #CAN-2409 $CADL proactiveinvestors.com/companies/news…

Dr. Paul Peter Tak (@paulpetertak) 's Twitter Profile Photo

Adam Feuerstein ✡️ Candel Therapeutics Manufacturing. While we continued to advance analytical development and comparability studies successfully, and locked the process, we did not want to spend tens of millions of $$ on large scale manufacturing before data read out - a concept that we call dynamic portfolio

Dr. Paul Peter Tak (@paulpetertak) 's Twitter Profile Photo

The collaboration between Candel Therapeutics and IDEA Pharma comes at a critical time as we prepare for our BLA submission for CAN-2409 in prostate cancer. Candel will gain access to a dedicated team of experts with extensive experience in oncology commercialization and

Jun Kim (@jun_kiim) 's Twitter Profile Photo

Combination of surgical upfront immunotherapy with aglatimagene besadenovec (CAN-2409), followed by chemoradiation and then adjuvant nivolumab for newly diagnosed glioblastoma (Wen et al. March 2025, SNO). E. Antonio Chiocca, MD, PhD, FAANS & Dr. Paul Peter Tak

Combination of surgical upfront immunotherapy with aglatimagene besadenovec (CAN-2409), followed by chemoradiation and then adjuvant nivolumab for newly diagnosed glioblastoma (Wen et al. March 2025, <a href="/NeuroOnc/">SNO</a>).

<a href="/EAChiocca/">E. Antonio Chiocca, MD, PhD, FAANS</a> &amp; <a href="/paulpetertak/">Dr. Paul Peter Tak</a>
Candel Therapeutics (@candeltx) 's Twitter Profile Photo

New in SNO! Our phase 1b trial of CAN-2409 + nivolumab in newly diagnosed high-grade glioma shows promising safety & survival data with immune activation supporting CAN-2409's pan-tumor potential. Read more: ir.candeltx.com/news-releases/… $CADL

New in <a href="/NeuroOnc/">SNO</a>! Our phase 1b trial of CAN-2409 + nivolumab in newly diagnosed high-grade glioma shows promising safety &amp; survival data with immune activation supporting CAN-2409's pan-tumor potential. 

Read more: ir.candeltx.com/news-releases/… 

$CADL
Dr. Paul Peter Tak (@paulpetertak) 's Twitter Profile Photo

Candel Therapeutics is set to host a webcast and conference call on Tuesday, June 3, 2025, at 1:00 PM ET. The event will delve into the promising phase 3 clinical results for CAN-2409 in localized, intermediate-to-high risk prostate cancer. These results showcased a notable 30%

Candel Therapeutics (@candeltx) 's Twitter Profile Photo

Join our investor conference call on Tuesday, June 3 at 1:00 PM ET following our #ASCO25 presentation. Our management team & leading prostate cancer specialists will discuss our phase 3 CAN-2409 results. Find more details here: ir.candeltx.com/news-releases/… $CADL #ProstateCancer

Join our investor conference call on Tuesday, June 3 at 1:00 PM ET following our #ASCO25 presentation. 

Our management team &amp; leading prostate cancer specialists will discuss our phase 3 CAN-2409 results. 

Find more details here: ir.candeltx.com/news-releases/… 

$CADL #ProstateCancer